Digest Network Come funziona
Network
/
Società
AN
Non verificato

AN2 Therapeutics, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaHIV, AIDS e malattie autoimmuniSaluteScienza

24 comunicati stampa

Guarda tutti i comunicati
12/11/2025
Scienza
Biotecnologia
Farmaceutica
Oncologia
Sanità
Salute
HIV, AIDS e malattie autoimmuni
Mercato azionario
AN2 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business and Scientific Highlights
Fonte
AN2 Therapeutics, Inc.
Emittente
Business Wire
1.00
0
10/11/2025
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Mercato del lavoro
Industria
AN2 Therapeutics Announces Research Collaboration With GSK to Advance Boron-Based LeuRS-Inhibitors Targeting Tuberculosis (TB)
Fonte
AN2 Therapeutics, Inc.
Emittente
Business Wire
1.00
0
06/11/2025
Eventi
Web e Social Network
Salute
HIV, AIDS e malattie autoimmuni
Scienza
Farmaceutica
Biotecnologia
AN2 Therapeutics to Participate in Fireside Chat at Evercore HealthCONx Conference
Fonte
AN2 Therapeutics, Inc.
Emittente
Business Wire
1.00
0
12/08/2025
Biotecnologia
HIV, AIDS e malattie autoimmuni
Salute
Farmaceutica
Oncologia
Web e Social Network
Telefonia e Varie
Mercato azionario
AN2 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business and Scientific Highlights
Fonte
AN2 Therapeutics, Inc.
Emittente
Business Wire
1.00
0
12/08/2025
Salute
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Industria
AN2 Therapeutics Commences First-in-Human Clinical Trial of Oral AN2-502998 for Chagas Disease
Fonte
AN2 Therapeutics, Inc.
Emittente
Business Wire
1.00
0
23/07/2025
Salute
HIV, AIDS e malattie autoimmuni
Scienza
Farmaceutica
Biotecnologia
Mercato del lavoro
AN2 Therapeutics and DNDi Collaborate on Clinical Development of Promising New Oral Compound to Treat Chronic Chagas Disease
Fonte
AN2 Therapeutics, Inc.
Emittente
Business Wire
1.00
0
30/06/2025
Scienza
HIV, AIDS e malattie autoimmuni
Igiene alimentare
Sanità
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Industria
AN2 Therapeutics Reports Key Insights from 200-Patient Observational Study in Acute Melioidosis, Laying Groundwork for Phase 2 Proof-of-Concept Trial of Epetraborole
Fonte
AN2 Therapeutics, Inc.
Emittente
Business Wire
1.00
0
29/05/2025
Biotecnologia
Farmaceutica
Salute
Eventi
AN2 Therapeutics Announces Poster Presentation Highlighting M. Abscessus Data at 2025 Colorado Mycobacteria Conference
Fonte
AN2 Therapeutics, Inc.
Emittente
Business Wire
1.00
0
13/05/2025
Mercato azionario
Biotecnologia
HIV, AIDS e malattie autoimmuni
Salute
Farmaceutica
Medicina - Varie
AN2 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business and Scientific Highlights
Fonte
AN2 Therapeutics, Inc.
Emittente
Business Wire
1.00
0
01/05/2025
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
HIV, AIDS e malattie autoimmuni
Medicina - Varie
AN2 Therapeutics Reports Data from the Phase 3 Portion of Previously Terminated EBO-301 Study and Outlines Future Milestones from Boron Chemistry Pipeline
Fonte
AN2 Therapeutics, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0